New anticoagulants for the prevention of venous thromboembolism

References

• GeertsWBergquistDPineoFPrevention of venous thromboembolism. American College of Chest Physicians’ evidence-based clinical practice guidelines (8th ed)Chest2008133381S453S18574271
   PubMed Web of Science ®Google Scholar
• CohenATTapsonVFBergmannJFVenous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): A multinational cross-sectional studyLancet200837138739418242412
   PubMed Web of Science ®Google Scholar
• HeitJAVenous thromboembolism: Disease burden, outcomes and risk factorsJ Thromb Haemost200531611161716102026
   PubMed Web of Science ®Google Scholar
• SeagroattVTanHSGoldcreMElective total hip replacement: Incidence, emergency readmission rate and postoperative mortalityBMJ1991303143114351773147
   PubMed Web of Science ®Google Scholar
• DahlOECapriniJAColwellCWFatal vascular outcomes following major orthopedic surgeryThromb Haemost20059386086615886800
   PubMed Web of Science ®Google Scholar
• PellegriniVDonaldsonCFarberDLehmanEEvartsCThe John Charnley Award: Prevention of readmission for venous thromboembolism disease after total hip arthroplastyClin Orthop2005441566216330984
   PubMed Web of Science ®Google Scholar
• DahlOEGudmundsenTEHaukelandLLate occurring clinical deep vein thrombosis in joint-operated patientsActa Orthop Scand200071475010743992
   PubMed Web of Science ®Google Scholar
• HeitJASilversteinMDMohrDNRisk factors for deep vein thrombosis and pulmonary embolism: A population based case-control studyArch Intern Med200016080981510737280
   PubMed Web of Science ®Google Scholar
• AndersonFAWheelerHBGoldbergRJA population based perspective of the hospital incidence and case fatality rates of deep vein thrombosis and pulmonary embolism: The Worcester DVT studyArch Intern Med19911519339382025141
   PubMed Web of Science ®Google Scholar
• SamamaMCohenATDarmonJYA comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patientsN Engl J Med199934179380010477777
   PubMed Web of Science ®Google Scholar
• WeitzJHirshJSamamaMMNew anticoagulant drugsChest2004126265S286S15383475
   PubMed Web of Science ®Google Scholar
• PrandoniPFalangaAPiccioliACancer and venous thromboembolismLancet Oncology2005640141015925818
   PubMed Web of Science ®Google Scholar
• KhoranaAFrancisCCulakovaEThromboembolism is leading cause of death in cancer patients receiving outpatient chemotherapyJ Thromb Haemost2007563263417319909
   PubMed Web of Science ®Google Scholar
• HeitJSilversteinMMohrDPettersonTO’FallonWMeltonLJRisk factors for deep vein thrombosis and pulmonary embolism: A population based case-control studyArch Intern Med200016080981510737280
   PubMed Web of Science ®Google Scholar
• AgnelliGGussoniGBianchiniCNadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind studyLancet Oncol20091094394919726226
   PubMed Web of Science ®Google Scholar
• GallusASPrevention of postoperative deep leg vein thrombosis in patients with cancerThromb Haemost1997781261329198141
   PubMed Web of Science ®Google Scholar
• FurieBFurieBCMolecular and cellular biology of blood coagulationN Engl J Med19923268008061538724
   PubMed Web of Science ®Google Scholar
• MannKButenasSBrummelKThe dynamics of thrombin formationArterioscler Thromb Vasc Biol200323172512524220
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMWensingGVoithBZuehlsdorfMSafety, pharmacodynamics and pharmacokinetics of BAY 59-7939, an oral, direct, Factor Xa inhibitor after multiple dosing in healthy male subjectsEur J Clin Pharmacol20056187388016328318
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMRothAMueckWDose escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjectsCurr Med Res Opin2008242757276518715524
   PubMed Web of Science ®Google Scholar
• WeinzCSchwartzTPleissJMetabolism and distribution of BAY 59-7939 – an oral, direct factor Xa inhibitor - in rat, dog and humanDrug Metab Rev200436196
   Web of Science ®Google Scholar
• SpyropoulosACBrave new world: The current and future use of novel anticoagulantsThrombosis Research200812329S35S
   Web of Science ®Google Scholar
• RaghavanNFrostCEYuZApixaban metabolism and pharmacokinetics after oral administration to humansDrug Metabolism and Disposition Fast Forward2009377481
   PubMed Web of Science ®Google Scholar
• KanHBingHGraceJEPreclinical pharmacokinetics and metabolism of apixaban, a potent and selective factor Xa inhibitorBlood2006108273
   Web of Science ®Google Scholar
• TurpieAGGNew oral anticoagulants in atrial fibrillationEur Heart J20082915516518096568
   PubMed Web of Science ®Google Scholar
• ZafarMVorcheimerDGaztanagaJAntithombotic effects of factor Xa inhibition with DU-176b: Phase I study of an oral direct factor Xa inhibitor using an ex-vivo flow chamberThromb Haemost20079888388817938815
   PubMed Web of Science ®Google Scholar
• ErikssonBTurpieALassenMA dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacementJ Thromb Haemost200751660166517663737
   PubMed Web of Science ®Google Scholar
• AgnelliGHaasSGinsbergJKruegerKDmitrienkoABrandtJA phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacementJ Thromb Haemost2007574675317408408
   PubMed Web of Science ®Google Scholar
• LassenMDavidsonBGallusAA Phase II randomized double blind, five-arm, parallel group, dose response study of a new oral acting Factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgeryBlood200310215
   Web of Science ®Google Scholar
• CohenAArmstrongDGazdzikTAn adaptative-design doseranging study of PD 0348292, a new oral factor Xa inhibitor, for the prophylaxis after total knee replacement surgeryBlood2008112 Abstr 980
   Google Scholar
• StangierJRathgenKStahleHGansserDRothWThe pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBr J Clin Pharmacol20076429230317506785
   PubMed Web of Science ®Google Scholar
• LassenMDahlOMismettiPDestréeDTurpieAGAVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery-TREK: A dose-ranging studyJ Thromb Haemost2009756657219187076
   PubMed Web of Science ®Google Scholar
• PerzbornEFactor Xa inhibitors. New anticoagulants for secondary haemostasisHamostaseologie20092926026719644596
   PubMedGoogle Scholar
• TurpieAFisherWBauerKBAY 59-7939: An oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging studyJ Thromb Haemost200532479248616241946
   PubMed Web of Science ®Google Scholar
• ErikssonBIBorrisLDahlOEOral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacementJ Thromb Haemost2006412112816409461
   PubMed Web of Science ®Google Scholar
• ErikssonBIBorrisLDahlOEA once-daily oral, direct Factor Xa inhibitor, Rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacementCirculation20061142374238117116766
   PubMed Web of Science ®Google Scholar
• ErikssonBIBorrisLCFriedmanRJRivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplastyN Engl J Med20083582765277518579811
   PubMed Web of Science ®Google Scholar
• LassenMRAgenoWBorrisLCRivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplastyN Engl J Med200835826
   Web of Science ®Google Scholar
• KakkarAKBrennerBDahlOEExtended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trialLancet20083723539
   Web of Science ®Google Scholar
• TurpieALassenMDavidsonBRivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): A randomized trialLancet20093731673168019411100
   PubMed Web of Science ®Google Scholar
• BauerKATurpieAGGLassenMRKakkarAKErikssonBIGentMEffect on age, weight, gender and renal function in a pooled analysis of four rivaroxaban studies. [abstract]J Thromb Haemost2009
   Google Scholar
• TurpieAGGLassenMRKakkarAKErikssonBIGentMPooled analysis of four rivaroxaban studies: effects on symptomatic events and bleeding. [abstract]Blood2008San Francisco CA
   Google Scholar
• Van ThielDKalodikiEWahiRLitinasEHaqueWRaoGInterpretation of benefit-risk of enoxaparin as comparator in the RECORD program: Rivaroxaban oral tablets (10 mg) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgeryClin Appl Thromb Haemost200915389394
   PubMed Web of Science ®Google Scholar
• LassenMRDavidsonBLGallusAPineoGAnsellJDeitchmanDThe efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacementJ Thromb Haemost200752368237517868430
   PubMed Web of Science ®Google Scholar
• LassenMRRaskobGEGallusAPineoGChenDPortmanRJApixaban or enoxaparin for thromboprophylaxis after knee replacementN Engl J Med200936159460419657123
   PubMed Web of Science ®Google Scholar
• LassenMGallusAPineoGRaskobGThe advance-2 study: A randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement. [abstract]J Thromb Haemost2009
   Google Scholar
• TurpieABauerKDavidsonBA randomized evaluation of betrixaban, an oral factor Xa inhibitor for prevention of thrombolic events after total knee replacement (EXPERT)Thromb Haemost2009101687619132191
   PubMed Web of Science ®Google Scholar
• FujiTFujitaSTachibanaSRandomized, double-blind, multidose efficacy, safety and biomarker study of the oral factor Xa inhibitor DU-176b compared with placebo for prevention of venous thromboembolism in patients after total knee arthroplastyBlood20081123418436740
   PubMed Web of Science ®Google Scholar
• RaskobGCohenAErikssonBRandomized double-blind multidose trial of the oral factor Xa inhibitor DU-176b versus LMW heparin (dalteparin) for prevention of venous thromboembolism after total hip replacementEur Heart J20082960918310671
   PubMed Web of Science ®Google Scholar
• ErikssonBITurpieAGLassenMRPrevention of venous thromboembolism with an oral Factor Xa inhibitor, YM150, after total hip arthroplasy. A dose-finding study (ONYX-2)J Thromb Haemost2010 Epub ahead of print. Blood. 2007;110:A309
   Web of Science ®Google Scholar
• ErikssonBIDahlOEAhnfeltLKäleboPDose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO IThromb Haemost2004215731580
   Web of Science ®Google Scholar
• ErikssonBIDahlOEBüllerHRHettiarachchiRA new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trialJ Thromb Haemost2005310311115634273
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOERosencherNDabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trialLancet200737094995617869635
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOERosencherNDabigatran etexilate versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trialJ Thromb Haemost200752178218517764540
   PubMed Web of Science ®Google Scholar
• The RE-MOBILIZE Writing CommitteeOral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regime for prevention of venous thromboembolism after knee arthroplasty surgeryThe Journal of Arthroplasty2009241
   Web of Science ®Google Scholar
• WolowaczSERoskellNSPlumbJMCapriniJAErikssonBIEfficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysisThromb Haemost2009101778519132192
   PubMed Web of Science ®Google Scholar
• AgnelliGBergqvistDCohenAGallusASGentMA randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high risk abdominal surgery: The PEGASUS studyBr J Surg2006106347352
   Google Scholar
• Di CarloVAgnelliGPrandoniPDermatan sulphate for the prevention of postoperative venouse thromboembolism in patients with cancer. DOS (Dermatan sulphate in Oncologic Surgery) Study GroupThromb Haemost199982303410456450
   PubMed Web of Science ®Google Scholar
• ENOXACAN Study GroupEfficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessmentBr J Surg199784109911039278651
   PubMed Web of Science ®Google Scholar
• BergqvistDAgnelliGCohenATFor ENOXACAN II InvestigatorsDuration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancerN Engl J Med200234697598011919306
   PubMed Web of Science ®Google Scholar